access to glp 1 GLP-1 Drugs Unequal for US Patients With Obesity New Medicare GLP-1 Bridge Program

Methods: By mining adverse event (AE) reports from the FAERS database covering the period from the first quarter of 2011 through the second quarter of 2024, baseline data were analyzed using Cramers V coefficient and p-value

Participants were recruited following the principles of the Declaration of Helsinki from the Division of Allergy and Immunology, Department of Dermatology, Venereology and Allergy, Campus Mitte and from the Division of Pediatric Allergy, Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Campus Virchow-Klinikum, with a known peanut allergy (allergic) or no food allergy (nonallergic)

Used as a fragrance

New and emerging systemic treatments for atopic dermatitis

It does